Search Results - "L. V Stelmashenko"

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma by Voloshin, S. V., Bessmeltsev, S. S., Zagoskina, T. P., Medvedeva, N. V., Kaplanov, K. D., Karyagina, E. V., Garifullin, A. D., Kuvshinov, A. Yu, Stelmashenko, L. V., Abdulkadyrov, K. M.

“…Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and…”
Get full text

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma by S. S. Bessmeltsev, L. V. Stelmashenko, N. V. Stepanova, K. M. Abdulkadyrov, G. N. Salogub, E. R. Machulaitene, E. V. Kariagina

“…We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years…”
Get full text

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma by S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov

“…Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib…”
Get full text

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade) by S. S. Bessmeltsev, E. V. Karyagina, L. V Stelmashenko, N. V. Stepanova, E. R. Machulaiten, G. N. Salogub, I. A. Skorokhod, N. V. Medvedeva, E. I. Podoltseva, L. M. Matyukhina, A. S. Nizamutdinova, K. M. Abdulkadyrov

“…The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are…”
Get full text

Modern strategies in therapy of elderly patients with multiple myeloma by S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova

“…We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients…”
Get full text

Lenalidomide for relapsed or refractory multiple myeloma by S. S. Bessmeltsev1, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina

“…We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34…”
Get full text

Lenalidomide for relapsed or refractory multiple myeloma by S. S. Bessmeltsev1, E. V. Kariagina, L. V. Stelmashenko, G. N. Salogub, E. R. Machulaitene, K. M. Abdulkadyrov, N. A. Kotova, I. I. Kostroma, N. V. Medvedeva, L. I. Krylova, E. Yu. Ilushkina

“…We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34…”
Get full text

Secondary myelodysplastic syndrome in patients with multiple myeloma by Abdulkadyrov, K M, Gritsaev, S V, Bessmel'tsev, S S, Martynkevich, I S, Tiranova, S A, Blinov, M N, Stel'mashenko, L V, Pesterova, V V

Get more information

Secondary myelodysplastic syndrome in patients with multiple myeloma by К М Abdulkadyrov, S V Gritsaev, S S Bessmeltsev, I S Matynkevich, S A Tiranova, M N Blinov, L V Stelmashenko, V V Pesterova

“…secondary myelodysplastic syndrome, multiple myeloma, complex karyotype impairments, treatment…”
Get full text

Diagnostic and prognostic significance of some laboratory indices of cerebrospinal fluid in multiple myeloma by Bessmel'tsev, S S, Lubo-Lesnichenko, I F, Abdulkadyrov, K M, Blinov, M N, Stel'mashenko, L V, Gubarenko, N K

“…beta 2-microglobulin (beta 2-m) and certain other characteristics of liquor have been followed in the course of multiple myeloma (MM) versus severity of the…”
Get more information

Effect of various chemotherapy regimens on survival and cause of death in patients with multiple myeloma (retrospective study) by Abdulkadyrov, K M, Bessmel'tsev, S S, Stel'mashenko, L V, Shmidt, A V, Rukavitsyn, O A

“…A retrospective analysis of survival time and causes of death has been undertaken in 109 patients treated for multiple myeloma (MM) at the Hematologic Clinic…”
Get more information

The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients by Lubo-Lesnichenko, I F, Bessmel'tsev, S S, Abdulkadyrov, K M, Blinov, M N, Stel'mashenko, L V

“…Pretreatment and treatment content of beta 2-microglobulin in blood serum was measured in 52 patients with multiple myeloma stage IIA, IIB, IIIA and IIIB. The…”
Get more information

Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma by Abdulkadyrov, K M, Stel'mashenko, L V, Bessmel'tsev, S S, Lubo-Lesnichenko, I F, Sel'tser, A V, Rozanova, O E, Gubarenko, N K, Bubnova, L N, Mnuskina, M M, Zhuchikhina, A A, Blinov, M N, Gritskevich, N L

“…The results of examination of 58 patients in the course of multiple myeloma (MM) are discussed. Prognosis for LDH, beta2-m and FNO-alpha administration was…”
Get more information